Gyre Therapeutics, Inc. (GYRE)
| Market Cap | 552.80M -33.1% |
| Revenue (ttm) | 117.05M +16.3% |
| Net Income | -6.36M |
| EPS | -0.08 |
| Shares Out | 91.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,463 |
| Open | 6.26 |
| Previous Close | 6.26 |
| Day's Range | 6.20 - 6.29 |
| 52-Week Range | 6.05 - 11.61 |
| Beta | 5.28 |
| Analysts | Strong Buy |
| Price Target | 18.67 (+208.6%) |
| Earnings Date | May 7, 2026 |
About GYRE
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated ... [Read more]
Financial Performance
In 2025, Gyre Therapeutics's revenue was $116.59 million, an increase of 10.24% compared to the previous year's $105.76 million. Earnings were $5.03 million, a decrease of -58.40%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for GYRE stock is "Strong Buy." The 12-month stock price target is $18.67, which is an increase of 208.60% from the latest price.
News
Gyre Therapeutics announces China NMPA acceptance of F351 NDA
Gyre Therapeutics (GYRE) announced that the Center for Drug Evaluation, or CDE, of China’s National Medical Products Administration, or NMPA, has accepted its new drug application, or NDA, for F351…
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operat...
Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year
Reports Q1 revenue $22.52M, consensus $31.61M. “Building on our successful pre-NDA meeting with China’s CDE at the beginning of the year, we are particularly encouraged by the NMPA’s priority review…
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to...
Gyre Therapeutics Earnings release: Q1 2026
Gyre Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Gyre Therapeutics Quarterly report: Q1 2026
Gyre Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflamm...
Gyre Therapeutics Proxy statement: Proxy filing
Gyre Therapeutics filed a proxy statement on May 4, 2026, providing details for shareholder voting and corporate governance matters.
Gyre Therapeutics Proxy statement: Proxy filing
Gyre Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Gyre Therapeutics Proxy statement: Proxy filing
Gyre Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Gyre Therapeutics Proxy statement: Proxy filing
Gyre Therapeutics filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Gyre Therapeutics’ liver fibrosis candidate granted priority review in China
Gyre Therapeutics (GYRE) announced that the Center for Drug Evaluation of China’s National Medical Products Administration, or NMPA, has granted priority review status to the New Drug Application for ...
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (Nasdaq: GYRE), a San Diego-based innovative commercial stage biopharmaceutical company with operation...
Gyre Therapeutics reports Q4 EPS (2c), consensus 1c
Reports Q4 revenue $37.2M, consensus $35.44M. “2026 is expected to be a pivotal regulatory year for Gyre as we advance Hydronidone toward conditional approval in China following our alignment with…
Gyre Therapeutics sees FY26 revenue $100.5M-$111M, consensus $148M
The company anticipates that 2026 will be a transition period, during which it plans to prioritize regulatory activities, including preparation for the planned NDA submission of Hydronidone. In additi...
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullg...
Gyre Therapeutics Annual report: Q4 2025
Gyre Therapeutics has published its Q4 2025 annual report on March 12, 2026.
Gyre Therapeutics Earnings release: Q4 2025
Gyre Therapeutics released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
Gyre Therapeutics (GYRE) announced its agreement to acquire Cullgen, a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader an...
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
Gyre Therapeutics (GYRE) announced its agreement to acquire Cullgen, a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader an...
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
Gyre Therapeutics (GYRE) announced its agreement to acquire Cullgen, a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader an...
Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a robust pipeline of degraders, targeting inflammatory diseases ...
Gyre Therapeutics Slides: Investor presentation
Gyre Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
Gyre Therapeutics Slides: Corporate presentation
Gyre Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on January 27, 2026.
Gyre Therapeutics announces alignment with China’s CDE on hydronidone
Gyre Therapeutics (GYRE) announced that its majority-owned subsidiary in China, Gyre Pharmaceuticals Co., Ltd., completed a Pre-New Drug Application communication meeting with the Center for Drug Eval...